Form 8-K - Current report:
SEC Accession No. 0000950170-24-017568
Filing Date
2024-02-21
Accepted
2024-02-21 07:45:22
Documents
13
Period of Report
2024-02-21
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K crsp-20240221.htm   iXBRL 8-K 45088
2 EX-99.1 crsp-ex99_1.htm EX-99.1 184137
  Complete submission text file 0000950170-24-017568.txt   357545

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT crsp-20240221.xsd EX-101.SCH 25983
14 EXTRACTED XBRL INSTANCE DOCUMENT crsp-20240221_htm.xml XML 4500
Mailing Address BAARERSTRASSE 14 ZUG V8 CH-6300
Business Address BAARERSTRASSE 14 ZUG V8 CH-6300 6173154600
CRISPR Therapeutics AG (Filer) CIK: 0001674416 (see all company filings)

EIN.: 473173478 | State of Incorp.: V8 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37923 | Film No.: 24656404
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)